Is Hindustan Bio Sciences Ltd (532041) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Hindustan Bio Sciences Ltd is a below average quality company .

Is Hindustan Bio Sciences Ltd (532041) undervalued or overvalued?

The key valuation ratios of Hindustan Bio Sciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Hindustan Bio Sciences Ltd (532041) share price return in the past 10 years?

Hindustan Bio Sciences Ltd share price has appreciated 14% annually (CAGR) over the past ten years.

Is Hindustan Bio Sciences Ltd (532041) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Hindustan Bio Sciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Hindustan Bio Sciences Ltd (532041)?

Company share prices are keep on changing according to the market conditions. The current trading price of Hindustan Bio Sciences Ltd (532041) on 17-Apr-2026 16:59:59 at 16:59 is 9.24.

What is the P/E ratio of Hindustan Bio Sciences?

The latest standalone P/E ratio of Hindustan Bio Sciences as of 17-Apr-2026 is 66.24.

What is the P/B ratio of Hindustan Bio Sciences Ltd (532041)?

The latest standalone P/B ratio of Hindustan Bio Sciences Ltd (532041) as of 17-Apr-2026 is 10.08.

What is the 52-week high and low of Hindustan Bio Sciences Ltd (532041)?

The 52-week high of Hindustan Bio Sciences Ltd (532041) is Rs. 10.32 and the 52-week low is Rs. 5.00.

Hindustan Bio Sciences Ltd (532041) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Hindustan Bio Sciences Ltd (532041)
Brand: Hindustan Bio Sciences

Hindustan Bio Sciences Ltd (532041) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Hindustan Bio Sciences Ltd (532041)

BSE: 532041 NSE:

Key Metrics

Market Cap

₹9 Cr.

P/E Ratio

66.24

Price to Book (P/B)

10.08

Price to Sales (P/S)

8.78

EV/EBITDA

74.98

Return on Capital Employed (ROCE)

2.94%

Current Price

₹9.2

Return on Equity (ROE)

11.78%

Return on Assets (ROA)

2.97%

Operating Profit Margin

12.6%

Net Profit Margin

12.38%

Gross Profit Margin

12.1%

Book Value per Share

₹0.9

Sales Growth (YoY)

-22.86%

Sales Growth (3 Years)

23.5%

Operating Profit Growth (1 Year)

66.67%

Operating Profit Growth (3 Years)

N/A%

Net Profit Growth (1 Year)

66.67%

52-Week Low / High

₹5 / 10

Net Profit Growth (3 Years)

N/A%

Dividend Yield

0.00%

Promoter Holding

12.19%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Hindustan Bio Sciences Ltd?

Hindustan Bio Sciences Ltd revenue growth is -22.9% for FY-2025 , which is below its 5 year CAGR of -16% , indicating slower growth.

Q.1 Promoter shareholding and pledge status of Hindustan Bio Sciences Ltd?

Promoters hold 12.19% of the Hindustan Bio Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Hindustan Bio Sciences Ltd vs industry peers?

Hindustan Bio Sciences Ltd revenue CAGR is -16.03% , compared to the industry median CAGR of 5.54% , indicating stable growth and maintaining its market share.

Q.1 Which industry/sub-sector does Hindustan Bio Sciences Ltd belong to?

Hindustan Bio Sciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Hindustan Bio Sciences Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 14% based on the current price.

DeciZen - make an informed investing decision on Hind Bio Science

Based on:

Data

M-Cap below 100cr DeciZen not available

Hindustan Bio Sciences stock performance

Key Ratios

Is Hindustan Bio Sciences Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-30.2%	-8.4%	-49%	2.7%	2.4%	-23.7%	-16.7%	-1.1%	1.7%	2.9%	-
Value Creation Index ⓘ	-3.2	-1.6	-4.5	-0.8	-0.8	-2.7	-2.2	-1.1	-0.9	-0.8	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1.3	1	1	3.6	1.9	1	0.4	0.9	1.1	0.8	1
Sales YoY Gr.	-	-19.8%	2%	245.6%	-45.5%	-46.9%	-58.3%	114%	14.1%	-22.9%	-
Adj EPS ⓘ	-0.7	-0.5	-2.2	0.1	0.1	-0.9	-0.5	-0	0.1	0.1	0.1
YoY Gr.	-	NA	NA	NA	-27.3%	-1237.5%	NA	NA	NA	66.7%	-
BVPS (₹) ⓘ	4.7	4.2	2	2.1	2.2	1.3	0.8	0.7	0.8	0.9	0.9
Adj Net Profit ⓘ	-0.7	-0.5	-2.3	0.1	0.1	-0.9	-0.5	-0	0.1	0.1	0
Cash Flow from Ops. ⓘ	0.5	-0.2	-0.2	-1.3	0.8	0.8	-0.3	-0.1	-1.4	0	-
Debt/CF from Ops. ⓘ	2.1	-8	-6.9	-2.6	3.2	2.5	-6.3	-49.3	-1.8	92.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-4.8%	-16%	23.5%	-22.9%
Adj EPS ⓘ	NA	4.6%	NA	66.7%
BVPSⓘ	-17%	-16.7%	4.6%	12.8%
Share Price	14%	27%	20.2%	10%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-12.7	-10.7	-71.3	5.3	3.7	-52.6	-49.2	-5.3	7.4	12	15.6
Op. Profit Mgn % ⓘ	-9.8	-46	-227.9	3.8	7	-90.3	-116.4	-3.1	6.1	12.6	16
Net Profit Mgn % ⓘ	-58.9	-48.6	-220.7	3.1	4.2	-90.5	-119.4	-4.4	5.5	12.6	13.3
Debt to Equity ⓘ	0.2	0.3	0.8	1.6	1.2	1.4	2.8	3.3	3.2	2.8	-
Working Cap Days ⓘ	1,673	2,069	1,653	459	1,001	1,543	2,688	1,219	1,134	1,499	60
Cash Conv. Cycle ⓘ	93	119	99	105	256	132	213	102	140	198	59

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	0.1	-
TTM Sales (₹ Cr.)	1.1	-
BVPS (₹) ⓘ	0.9	-
Reserves (₹ Cr.) ⓘ	-1	-
P/BV ⓘ	10.08	-
PE ⓘ	66.24	-

From the Market
52 Week Low / High (₹)	5.00 / 10.32
All Time Low / High (₹)	0.10 / 106.65
Market Cap (₹ Cr.)	9.5
Equity (₹ Cr.)	2.1
Face Value (₹)	2
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Hind Bio Science - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	1.26	1.01	1.03	3.56	1.94	1.03	0.43	0.92	1.05	0.81
Operating Expenses ⓘ +	1.38	1.48	3.38	3.43	1.81	1.97	0.94	0.95	0.99	0.71
Manufacturing Costs	0.03	0.05	0.04	0.03	0.02	0.01	0.01	0	0	0
Material Costs	0.86	0.73	0.57	2.89	1.30	0.68	0.24	0.57	0.64	0.49
Employee Cost	0.22	0.21	0.16	0.16	0.20	0.19	0.18	0.18	0.09	0.07
Other Costs ⓘ	0.28	0.49	2.61	0.35	0.29	1.09	0.51	0.20	0.26	0.15
Operating Profit ⓘ	-0.12	-0.47	-2.35	0.13	0.14	-0.94	-0.51	-0.03	0.06	0.10
Operating Profit Margin (%)	-9.8%	-46.0%	-227.0%	3.7%	7.0%	-91.1%	-117.0%	-3.1%	6.1%	12.3%
Other Income ⓘ +	0	0	0.09	0	0	0	0	0	0	0
Exceptional Items ⓘ	-1.92	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.03	0.01	0	0.01	0.01	0.01	0	0	0	0
Depreciation ⓘ	0.01	0.01	0.01	0.01	0.01	0.01	0	0.01	0.01	0
Profit Before Tax ⓘ	-2.08	-0.49	-2.27	0.11	0.12	-0.96	-0.51	-0.04	0.05	0.10
Tax ⓘ	0	0	0	0	0.04	-0.02	0	0	-0	-0
Profit After Tax	-2.09	-0.49	-2.28	0.11	0.08	-0.94	-0.52	-0.04	0.06	0.10
PAT Margin (%)	-165.0%	-48.6%	-220.0%	3.1%	4.2%	-91.1%	-120.0%	-4.4%	5.5%	12.4%
Adjusted EPS (₹)	-2.0	-0.5	-2.2	0.1	0.1	-0.9	-0.5	-0.0	0.1	0.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	4.82	4.33	2.05	2.16	2.24	1.30	0.79	0.75	0.80	0.90
Share Capital ⓘ	10.25	10.25	10.25	10.25	10.25	10.25	10.25	2.05	2.05	2.05
Reserves ⓘ	-5.43	-5.92	-8.20	-8.09	-8.01	-8.95	-9.46	-1.30	-1.25	-1.15
Debt +	0.94	1.30	1.57	3.37	2.60	1.86	2.17	2.46	2.56	2.51
Long Term Debt	0.36	0.55	0.76	2.47	1.67	0.73	1.07	1.12	2.56	2.51
Short Term Debt	0.58	0.75	0.81	0.89	0.93	1.13	1.09	1.33	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0.09	0.21	0.07	0.06	0.66	0.29	0	0.06	0	0
Others Liabilities ⓘ	-0.01	-0	-0.01	0.01	0.04	0.02	0.02	0.02	0	0
Total Liabilities ⓘ	5.84	5.84	3.68	5.60	5.55	3.48	2.97	3.28	3.37	3.41
Fixed Assets
Net Fixed Assets ⓘ +	0.07	0.06	0.06	0.06	0.05	0.04	0.04	0.03	0.03	0.03
Gross Block	0.53	0.53	0.54	0.54	0.54	0.54	0.55	0.55	0.55	0.55
Accumulated Depreciation	0.46	0.47	0.48	0.48	0.49	0.50	0.51	0.51	0.52	0.52
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	0	0	0.08	0.11	0.34	0	0	0	0	0
Trade Receivables	0.47	0.47	0.32	1.67	1.36	0.62	0.14	0.45	0.44	0.44
Cash Equivalents	0.03	0.04	0.02	0.18	0.20	0.02	0.01	0.01	0.04	0.01
Others Assets ⓘ	5.27	5.27	3.21	3.57	3.60	2.80	2.79	2.79	2.86	2.93
Total Assets ⓘ	5.84	5.84	3.68	5.60	5.55	3.48	2.97	3.28	3.37	3.41

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	0.46	-0.16	-0.23	-1.32	0.82	0.75	-0.34	-0.05	-1.41	0.03
PBT ⓘ	-0.16	-0.49	-2.27	0.11	0.12	-0.96	-0.51	-0.04	0.05	0.10
Adjustment ⓘ	0.04	0.02	0.01	0.01	0.01	0.04	0.23	0.01	0.01	0
Changes in Working Capital ⓘ	0.58	0.31	2.03	-1.45	0.71	1.65	-0.06	-0.02	-1.47	-0.07
Tax Paid ⓘ	0	0	0	0	-0.02	0.02	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-0	-0	-0	-0.01	0	0	-0	0	0	0
Capex	-0	-0	-0	-0.01	0	0	-0	0	0	0
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	-0.63	0.18	0.21	1.50	-0.81	-0.93	0.34	0.05	1.43	-0.05
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0.60	0.19	0.22	1.50	-0.81	-0.93	0.34	0.05	1.43	-0.05
Interest Paid ⓘ	-0.02	-0.01	-0	-0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Net Cash Flow ⓘ	-0.17	0.01	-0.02	0.17	0.01	-0.18	-0.01	0	0.03	-0.02

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-35.6	-10.74	-71.3	5.22	3.67	-52.96	-49.49	-5.28	7.43	11.78
ROCE (%)	-30.17	-8.37	-49.03	2.68	2.4	-23.7	-16.66	-1.1	1.74	2.94
Asset Turnover Ratio	0.18	0.17	0.22	0.77	0.35	0.23	0.13	0.3	0.32	0.24
PAT to CFO Conversion(x)	N/A	N/A	N/A	-12	10.25	N/A	N/A	N/A	-23.5	0.3
Working Capital Days
Receivable Days	115	170	139	102	285	350	319	116	155	198
Inventory Days	13	0	28	10	43	0	0	0	0	0
Payable Days	50	76	89	8	102	255	225	21	19	1

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Hindustan Bio Sciences Ltd FAQs

The current trading price of Hind Bio Science on 17-Apr-2026 16:59 is ₹9.24.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Hind Bio Science stood at ₹9.47 Cr

The latest P/E ratio of Hind Bio Science as of 16-Apr-2026 is 66.24.

The latest P/B ratio of Hind Bio Science as of 16-Apr-2026 is 10.08.

The 52-week high of Hind Bio Science is ₹10.32 and the 52-week low is ₹5.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Hind Bio Science is ₹1.08 ( Cr.) .

About Hindustan Bio Sciences Ltd

Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society.

The company started its activities in the year 2001 and has been identifying potential recombinant DNA based biopharmaceutical products for marketing in India. The company has outsourced the manufacturing activity presently and the owned manufacturing facilities will be established at a latter stage. At present the company is setting up a research and development facility for developing the R DNA based biopharmaceuticals for human consumption. The company has finalized a technical consultation tie-up with CCMB (Centre for Cellular and Molecular Biology).

Products

The company has obtained the approval of Genetic Engineering Approval Committee (GEAC) for import and marketing of Recombinant Human Erythropoietin manufactured by M/s. Shandong Kexing Bioproducts Co., Shandong, China. The protocol submitted by the company to conduct clinical trials has been approved by DCGI (Drug Controller General of India) and ethics committees of concerned Hospitals.

Hindustan Bio Sciences, engages in the import and marketing of recombinant deoxyribonucleic acid products for the treatment of life threatening diseases in India. It markets human erythropoietin manufactured by Shandong Kexing Bioproducts Co.

In 2001 the company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd (R&T agents) for dematerialization. In 2004 Hindustan Bio bagged GEAC nod recombinant human erythropoietin.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Hindustan Bio Sciences Ltd (532041) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Hind Bio Science Share Price